Tumor Control Durable With Pembrolizumab in Merkel Cell Cancer
WEDNESDAY, Feb. 27, 2019 -- For patients with advanced Merkel cell carcinoma (aMCC), pembrolizumab is associated with durable tumor control and favorable overall survival, according to a study published online Feb. 7 in the Journal of Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2019 Category: Pharmaceuticals Source Type: news
Immunotherapy drug used as 1st-line therapy for Merkel cell carcinoma improved survival
(Louisiana State University Health Sciences Center) A multi-center phase II clinical trial investigating pembrolizumab as a first-line and programmed cell death-1 therapy in patients with advanced Merkel cell carcinoma reports lasting tumor control, generally manageable side effects and improved overall survival. Dr. Adam Riker led the study at LSU Health New Orleans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2019 Category: International Medicine & Public Health Source Type: news
Immunotherapy appears better than chemotherapy for aggressive type of skin cancer
(Johns Hopkins Medicine) The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 7, 2019 Category: International Medicine & Public Health Source Type: news
Skin Cancer | Medscape Skin Cancer | Medscape
Nonmelanoma skin cancer primarily comprises basal cell carcinoma and squamous cell carcinoma. Other, rarer types of nonmelanoma skin cancer include dermatofibrosarcoma protuberans, Merkel cell carcinoma, and Kaposi ' s sarcoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news
Is First-Line Avelumab Effective for Metastatic Merkel Cell Carcinoma?
Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving avelumab monotherapy. (Source: CancerNetwork)
Source: CancerNetwork - November 14, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Skin Cancer Merkel Cell Carcinoma
Skin Cancer: Merkel Cell Carcinoma (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2018 Category: General Medicine Source Type: news
Incidence of Merkel Cell Carcinoma Rising Sharply
The incidence of Merkel cell carcinoma, an aggressive neuroendocrine skin cancer, has grown rapidly since the disease was first described in 1972. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Skin Cancer Source Type: news
Aggressive Skin Cancer Rates Skyrocketing Aggressive Skin Cancer Rates Skyrocketing
The incidence of Merkel cell carcinoma is increasing exponentially as the US population ages, a new national study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 19, 2018 Category: Consumer Health News Tags: Dermatology News Source Type: news
Immunotherapy for Merkel cell carcinoma -- novel research highlights quality of life benefits
(Future Science Group) Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news
Merkel Cell Carcinoma: Not Just Another Skin Cancer Merkel Cell Carcinoma: Not Just Another Skin Cancer
Merkel cell expert Paul Nghiem, MD, PhD, explains how this rare but deadly condition differs from other forms of skin cancer.Medscape Dermatology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 27, 2017 Category: Pathology Tags: Dermatology Expert Interview Source Type: news
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK
Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland
Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news
Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
FRANKFURT (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU
Decision by the EC is expected in the third quarter of 2017
Not intended for UK-based media
DARMSTADT, Germany and NEW YO... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, BAVENCIO, avelumab, metastatic Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 21, 2017 Category: Pharmaceuticals Source Type: news
Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval
(Reuters) - European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial
(Fred Hutchinson Cancer Research Center) Combo of T-cell therapy, newly FDA-approved drug and another immunotherapeutic agent kept cancer at bay for three out of four patients with metastatic Merkel cell carcinoma. The findings will be presented June 5 at the annual meeting of the American Society of Clinical Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2017 Category: Cancer & Oncology Source Type: news
